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OBJECTIVES The objective of this study was to evaluate the effect of estrogen compared to estrogen plus
progesterone on the stress electrocardiogram (ECG) in relationship to stress-gated myocar-
dial perfusion imaging (MPI) in postmenopausal women.
BACKGROUND It is generally recognized that estrogen may cause false positive ST depressions on the stress
ECG. The effects of estrogen plus progesterone are not known. This study was performed to
define the effects of these agents on the stress ECG correlated with results from MPI.
METHODS We evaluated 140 postmenopausal women—31 not taking any hormone replacement therapy
(HRT); 75 taking estrogen alone; and 34 taking estrogen plus progesterone. Women with a
history of coronary artery disease (CAD), cardiomyopathy, or an abnormal resting ECG were
excluded. All women underwent a symptom-limited treadmill test and MPI.
RESULTS The overall sensitivity and specificity of the stress ECG compared to MPI in women not
taking HRT was 54% and 78%, respectively. In women taking estrogen or estrogen plus
progesterone, the sensitivity was unchanged. The power to detect clinically meaningful
sensitivity difference (10%) was poor (p  0.09). The specificity was reduced to 46% (p 
0.01) in women on estrogen therapy. In women taking estrogen plus progesterone, specificity
was 80%.
CONCLUSIONS Our results suggest that estrogen increases the false positive rate of the stress ECG. This
decreased specificity is countered by co-administration of progesterone. Nonetheless, because
the sensitivity of the stress ECG is only 50% to 57% in postmenopausal women, women at
risk should have imaging in conjunction with stress for the optimal detection of
CAD. (J Am Coll Cardiol 2002;40:1092–6) © 2002 by the American College of
Cardiology Foundation
In Western societies, coronary artery disease (CAD) has
now become the leading cause of death in women (1).
Although the prevalence of CAD in women is lower than in
men during the third through fifth decade, the incidence
increases thereafter, and by the time women reach the
eighth decade, the prevalence of CAD actually exceeds that
of men (2). In addition, women have poor outcomes when
they do manifest CAD compared to men (3,4).
Despite this high prevalence and poor outcome, the
diagnosis of CAD in women is more complex because
women present with more atypical than typical anginal
features. Although stress electrocardiography (ECG) is
widely available and is relatively inexpensive, the sensitivity
and especially the specificity rates of the stress ECG are
lower in women than in men (5–7). This is believed to be
related both to the lower work loads achieved by women
when corrected for age, and the putative effect of estrogen
on the stress ECG (8,9). Thus, women are 5 to 20 times
more likely to have a false positive stress ECG than men (8).
As a result of this lower specificity, the best diagnostic
strategy for the detection of CAD in women remains
controversial. Although the high prevalence of false positive
findings on the exercise ECG has been attributed to the
presence of higher estrogen levels (9), the exact cause of the
lower specificity in women is not clear. In addition, estrogen
levels decrease after menopause, but the specificity of the
ECG still is low. Thus, the effects of estrogen in combina-
tion with progesterone on the exercise ECG are not well
known (10).
Accordingly, we evaluated the effect of estrogen with or
without progesterone on the exercise ECG in postmeno-
pausal women presenting to the stress laboratory for symp-
toms believed to relate to CAD, and to correlate changes
with results of myocardial perfusion imaging (MPI).
METHODS
Subjects. We performed a retrospective study on 140
consecutive postmenopausal women referred for the diag-
nosis of chest pain or dyspnea on exertion by either their
primary care physician or cardiologist. Postmenopausal
status was defined as age more than 50 years with cessation
of menses for at least six months before the test period.
Patients with classic angina or documented CAD, cardio-
myopathy, and those with abnormal ECGs (left bundle
branch block, paced rhythm, ECG criteria of left ventricular
hypertrophy, delta waves suggestive of Wolff-Parkinson-
White syndrome, patients on digitalis, or patients with
resting ST-T wave changes) were excluded. Patients who
could not achieve 85% of age-adjusted predicted maximum
heart rate (calculated as 220  age) during exercise stress
testing and those who did not achieve age-corrected Bruce
protocol exercise times were also excluded.
Patients were divided into three groups: those receiving
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no hormone replacement therapy (HRT); those receiving
estrogen replacement therapy (ERT) alone; and those re-
ceiving estrogen plus progesterone replacement therapy
(EPRT). Patients in the no-HRT group ranged in age from
52 to 76 years (mean 64  7 years). Those in the ERT
group ranged in age from 51 to 74 years (mean 61 8 years)
and were taking 0.625 mg of conjugated estrogen daily by
mouth. Patients in the EPRT group ranged in age from 53
to 78 years (mean 63  7 years) and were taking 0.625 mg
of conjugated estrogen plus 2.5 or 5.0 mg of medroxypro-
gesterone daily by mouth. Patients in the ERT and EPRT
groups had been taking their medication for at least six
months prior to the exercise test. No statistically significant
difference existed between the groups on the basis of risk
factors (Table 1).
Study protocol. All patients underwent symptom-limited
treadmill exercise testing with the Bruce protocol. Medica-
tions were withheld for at least 12 h prior to the test. All
patients had gated single-photon emission computed tomo-
graphic (SPECT) MPI performed in conjunction with
stress testing.
Stress ECG. During stress testing, each patient had ECGs
recorded with 12-limb and left precordial ECG leads. The
skin was cleansed vigorously with alcohol, and ECG leads
were placed. Treadmill testing was performed on Marquette
ECG machines (model Case 15, Marquette Electronics,
Milwaukee, Wisconsin). ECGs were recorded continuously
before and during stress testing and for up to 10 min during
the recovery period. Raw and averaged ECGs were then
analzed separately by two physicians with extensive stress-
testing experience and who were blinded to HRT status.
The ST-segment changes during stress were considered
positive if there was horizontal or downsloping ST-segment
depression of at least 1 mm at 80 ms after the J point
compared with the baseline ECG, or an upsloping ST-
segment depression of at least 1.5 mm at 80 ms after the J
point compared with the baseline ECG. The line between
two PR segments was used as a baseline. Changes needed to
be observed in two contiguous leads to be considered
positive. Equivocal changes not meeting the above criteria
for ischemia were reported as such to the patients’ referring
physicians, but they were included in the normal ECG
category for the purpose of this study.
MPI. Radionuclide perfusion imaging was performed with
two different protocols: thallium-201 (Tl-201) stress-
redistribution scanning or a dual-isotope protocol. In the
thallium protocol, patients received approximately 3.0 to 3.3
mCi of Tl-201 intravenously at peak stress. Exercise was
continued for 60 to 90 s after radioisotope injection, and
gated stress SPECT imaging commenced within 10 min
from the time of injection. All patients then had redistri-
bution scans obtained at 3 to 4 h. Thallium imaging was
performed on a triple-headed Picker camera (PRISM
3000XP, Picker International Inc., Highland Heights,
Ohio) with a 360° acquisition.
In the dual-isotope protocol, patients received approxi-
mately 3.0 to 3.3 mCi of Tl-201 at rest and had rest
SPECT MPI performed 15 to 30 min after injection. They
then received 25 to 30 mCi of technetium-99m sestamibi at
peak stress, exercised for 60 to 120 s more, and underwent
stress imaging approximately 30 to 60 min later. Dual-
isotope imaging was performed on a dual-headed ADAC
Cardio-Epic camera (ADAC Laboratories, Milpitas, Cali-
fornia) with a 180° acquisition (from 45° right anterior
oblique to 225° left posterior oblique). All scans were
collected in the gated mode, which allows interpretation of
wall motion and ejection fraction from gated myocardial
perfusion images. All scans were interpreted both qualita-
tively and quantitatively with standard, commercially avail-
able software.
Scans were interpreted by physicians with extensive
experience blinded to patient’s HRT status. Scans were
considered normal if uptake of tracer during stress was
homogeneous and if results of wall motion and ejection
fraction from gated imaging were normal. Scans were
considered to reflect ischemia if there was a stress-induced
defect that was not observed or had decreased significantly
on the redistribution or resting scans. Infarction was defined
as a focal decrease in radionuclide concentration with stress
that was unchanged at rest or redistribution and that had a
Abbreviations and Acronyms
CAD  coronary artery disease
ECG  electrocardiogram/electrocardiography
EPRT  estrogen plus progesterone replacement
therapy
ERT  estrogen replacement therapy
HRT  hormone replacement therapy
MPI  myocardial perfusion imaging
MVD  multivessel disease
SPECT  single-photon emission computed
tomographic imaging
SVD  single-vessel disease
Tl-201  thallium-201
Table 1. Patients’ Baseline Characteristics
No HRT
(n  31)
ERT
(n  75)
EPRT
(n  34)
Age (yrs) 64  8 61  8 63  7
Family history of CAD 5 (18%) 16 (21%) 7 (20%)
Hypertension 14 (47%) 39 (52%) 17 (49%)
Diabetes mellitus 3 (11%) 7 (9%) 2 (6%)
Hypercholesterolemia 7 (28%) 25 (33%) 10 (29%)
Smoking 6 (21%) 14 (19%) 8 (23%)
Exercise duration (min)  SD 6  1 6  1 7  2
Peak HR (beats/min)  SD 140  19 140  18 139  16
Peak SBP (mm Hg)  SD 159  21 158  23 159  22
No significant differences were seen in the three groups. Family history of CAD 
first-degree male relatives with coronary artery disease before 55 years of age, female
relatives before 65 years of age. Hypertension SBP140 mm Hg or DBP90 mm
Hg. Diabetes mellitus  fasting blood glucose 126 mg/dl. Hypercholesterolemia 
cholesterol 200 mg/dl, low-density lipoprotein 160 mg/dl.
CAD  coronary artery disease; DBP  diastolic blood pressure; EPRT 
estrogen plus progesterone replacement therapy; ERT  estrogen replacement
therapy; HR  heart rate; HRT  hormone replacement therapy; SBP  systolic
blood pressure.
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regional wall motion abnormality in the same segment.
Single-vessel disease (SVD) was defined as a scintigraphic
pattern characterized by the presence of perfusion defects in
only one coronary artery territory, and multivessel disease
(MVD) was defined by the presence of perfusion defects in
two or more coronary artery territories.
Statistics. Results of the stress ECG were compared with
MPI results. The overall sensitivity of stress-gated MPI in
our laboratory compared with cardiac angiography (50%
coronary luminal narrowing defined as angiographic ob-
struction) is 93%.
Data are presented as mean  SD. Differences between
groups were compared with the Fisher exact test, with p 
0.05 considered statistically meaningful. Continuous vari-
ables were compared using analysis of variance, while the
differences of categorical variables were assessed by the
chi-square test.
RESULTS
Of the 140 women, 31 were in the no-HRT group, 75 were
in the ERT group, and 34 were in the EPRT group. No
statistically significant difference was seen in exercise dura-
tion, peak heart rate, or peak systolic blood pressure between
groups (Table 1).
For the purposes of this study, an abnormal scan was that
in which ischemia or infarction was present. Of the total of
59 patients with abnormal scans, all had ischemia and 3 had
a combination of both ischemia and infarction. Thus, the
majority of patients with “abnormal” scans had ischemia.
Of the 31 postmenopausal women taking no HRT, 11
(35%) had a positive stress ECG and 20 (65%) had a
negative stress ECG. Of 11 women with positive stress
ECG, 7 (64%) had an abnormal MPI (4 SVD; 3 MVD). Of
20 women with negative stress ECG, 6 (30%) had an
abnormal MPI (5 SVD; 1 MVD) (Fig. 1). Overall, the
sensitivity of the stress ECG compared with MPI in the
group was 54%, and specificity was 78% (Fig. 2). The
sensitivity of the stress ECG for detecting SVD in this
group of women was 44%, and it was 75% for detecting
MVD (Fig. 3).
Of the 75 women in the ERT group, 41 (55%) had a
positive ECG on stress testing and 34 (45%) had a negative
stress ECG. Of 41 women with positive ECGs, 18 (45%)
had an abnormal myocardial perfusion scan (8 SVD; 10
MVD). Of 34 women with negative ECGs, 14 (41%) had
abnormal MPI (11 had SVD; 3 had MVD) (Fig. 1).
Figure 1. Flow diagram of the postmenopausal women studied. Abnormal scans predominantly reflect ischemia (see text). ECG  electrocardiogram;
EPRT  estrogen plus progesterone replacement therapy; ERT  estrogen replacement therapy; HRT  hormone replacement therapy.
Figure 2. Overall sensitivity and specificity for the stress ECG compared to
gated myocardial perfusion imaging in the groups. *p  0.01. Solid bar 
No HRT; lined bar  ERT; open bar  EPRT. For abbreviations, see
Figure 1.
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Compared with MPI, in women taking ERT the overall
sensitivity of the stress ECG was 56%, and the specificity
was 46% (Fig. 2). The sensitivity for detecting SVD was
42%, and it was 78% for detecting MVD (Fig. 3).
Of the 34 women taking EPRT, 12 (35%) had positive
ECGs on stress testing and 22 (65%) had negative stress
ECGs. Of the 12 with positive stress ECGs, 8 (67%) had
positive MPI (4 SVD; 4 MVD). Of 22 women with
negative ECGs, 6 (27%) had positive MPI (5 SVD; 1
MVD) (Fig. 1). Sensitivity was therefore 57%, and speci-
ficity was 80% (Fig. 2). The sensitivity for detecting SVD in
women on EPRT was 44%, and it was 80% for detecting
MVD (Fig. 3).
Thus, comparing the stress ECG to gated MPI, no
significant difference was seen between the sensitivity of
detecting CAD in women between those on ERT, EPRT,
or those not taking HRT (Figs. 2 and 3). In contrast, the
specificity of the women taking EPRT or those not taking
HRT was significantly higher than those women taking
estrogen alone (p  0.01) (Fig. 2).
DISCUSSION
Our results show that postmenopausal women referred for
chest pain or dyspnea with an intermediate likelihood of
CAD and taking estrogen alone have a higher rate of false
positive ST-segment changes on the exercise stress ECG
compared with patients taking a combination of estrogen
plus progesterone or those not taking HRT.
Exercise ECG. Exercise ECG testing began with the
observation of abnormal downsloping ST-depression and
T-wave inversion in the ECG of three male patients
experiencing anginal attacks after climbing the stairs to a
physician’s office in 1928 (11). Profant was the first to report
that exercise-induced ST-depression was more common in
normal women than in men (12). Concerning the effects of
hormones, the earliest study was by Jaffe (13), who observed
ST-segment changes in 51 patients (33 men, 18 women)
after two weeks of estogen therapy and reversal of the effect
six weeks after discontinuation. A study by Morise et al. (9)
found positive ECG treadmill stress tests in 22% (24/109)
of postmenopausal women with normal coronary angio-
grams. Fourteen of 24 (58%) patients were receiving estro-
gen HRT. Rovang et al. (14) performed treadmill exercise
echocardiography in 47 postmenopausal women free of
CAD prior to and following six weeks of ERT therapy.
Additionally, 10 women (21%) with negative ECGs at
baseline had positive ECG response after ERT replacement
therapy without new wall motion abnormalities on echocar-
diography (15).
Several studies have documented the lack of diagnostic
value of the stress ECG in women on ERT (sensitivity
ranging from 0.32 to 0.80; specificity from 0.41 to 0.68)
(16,17). Compared with the exercise ECG, stress MPI
offers improved sensitivity (83% to 90%) and specificity
(80% to 93%), especially when combined with gating
(18,19). Also, MPI is a more accurate predictor of prognosis
than either the exercise ECG or even coronary angiography
(20).
The mechanism of the false positive exercise ECG
response to estrogen is unknown. Several explanations have
been proposed. Estrogen has a similar chemical structure to
digitalis, a known cause of false positive ST-depression (21).
There is also some evidence that estrogen may be a
vasoconstrictor to coronary arterioles (22). The true cause of
the increased false positive rate of exercise tests is neverthe-
less still being debated. Conversely, androgens have been
shown to decrease ST-depression (23), and though the exact
mechanism by which progesterone acts on ST-segments is
unknown, it is possible that this androgen effect balances the
effects of estrogen.
Study limitations. Our study was limited in that none of
the patients in our study underwent coronary angiography,
presently considered the gold standard for the diagnosis of
CAD. Although angiography is more accurate for the
diagnosis of CAD, studies based on invasive techniques are
more likely to be influenced by referral bias (24). In our
study, gated MPI was the noninvasive strategy used for
delineation of myocardial perfusion abnormalities. Exercise
MPI has a good diagnostic accuracy, with an overall
sensitivity of 83% to 90% and an overall specificity of 80%
to 93% (17,18). In addition, the use of gating greatly
improves the specificity of interpretation of MPI, especially
in women (18).
Significant differences in sensitivity were not detected in
this study. This is not surprising as the power to detect
sensitivity differences of 10% was only 0.09, whereas the
power to detect the actual observed differences in sensitivity
was 0.04 (alpha  0.05).
Conclusions. In summary, the stress ECG is more specific
in postmenopausal women not taking HRT or those taking
Figure 3. Specificity of the stress ECG compared to gated myocardial
perfusion imaging in the postmenopausal women studied for detecting
coronary artery disease in those with single-vessel as compared to mul-
tivessel disease. Solid bar  No HRT; lined bar  ERT; open bar 
EPRT. For abbreviations, see Figure 1.
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a combination of estrogen and progesterone than in patients
taking estrogen alone. However, the overall sensitivity for
detection of CAD in women based on the stress ECG in
comparison with MPI is only about 50% and not related to
estrogen. Thus, even though the stress ECG is more specific
in postmenopausal women either not taking HRT or on
EPRT, women referred for stress testing should undergo
imaging for optimal detection of CAD.
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